Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc. (MAZE), sold 15,000 shares at $26.22 ($393K) on 2026-05-14, disclosed to the SEC on 2026-05-18.
Scheduled sale ($393k) by President, R&D & CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| MAZE | SELL | 2026-09-04 | $270K | — | Filing → |
| MAZE | SELL | 2026-09-03 | $426K | — | Filing → |
| MAZE | SELL | 2026-08-14 | $446K | — | Filing → |